Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Title
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Authors
Keywords
-
Journal
CLINICAL CANCER RESEARCH
Volume 27, Issue 16, Pages 4491-4499
Publisher
American Association for Cancer Research (AACR)
Online
2021-06-03
DOI
10.1158/1078-0432.ccr-21-0611

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started